Chronic rhinosinusitis with nasal polyps biologic class matures
Dupilumab maturity, mepolizumab and benralizumab CRSwNP indications, omalizumab CRSwNP approval, and emerging mechanism programs are reshaping CRSwNP management.
Chronic rhinosinusitis with nasal polyps (CRSwNP) has been a corticosteroid (intranasal and oral burst) and surgical category for years. Dupilumab carries CRSwNP approval, mepolizumab and benralizumab have CRSwNP indications, omalizumab is approved, and tezepelumab pivotal data in CRSwNP is reading out. The category has gone from procedural-default to a competitive biologic prescribing class in five years; the surgery-vs-biologic decision is the modern clinical conversation.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.